How were BioSpecifics Technologies' earnings last quarter?

BioSpecifics Technologies Corp. (NASDAQ:BSTC) announced its quarterly earnings data on Saturday, November, 14th. The biopharmaceutical company reported $0.89 EPS for the quarter, topping analysts' consensus estimates of $0.19 by $0.70. The biopharmaceutical company had revenue of $11.26 million for the quarter, compared to analyst estimates of $5.46 million. BioSpecifics Technologies had a net margin of 47.43% and a trailing twelve-month return on equity of 14.81%.

What other stocks do shareholders of BioSpecifics Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioSpecifics Technologies investors own include AbbVie (ABBV) , NVIDIA (NVDA) , Pfizer (PFE) , Biogen (BIIB) , Johnson & Johnson (JNJ) , Horizon Therapeutics Public (HZNP) , Inovio Pharmaceuticals (INO) , Intel (INTC) , Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP) .

NASDAQ:BSTC

BioSpecifics Technologies (BSTC) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free BSTC Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $88.53
▼
$88.53
50-Day Range: $88.22
▼
$88.53
52-Week Range: $42.00
▼
$89.15

Volume: N/A
Average Volume: 61,105 shs
Market Capitalization: $650.25 million

P/E Ratio: 37.51
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get BioSpecifics Technologies alerts:

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About BioSpecifics Technologies Stock (NASDAQ:BSTC)

BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

BSTC Stock News Headlines

March 21, 2023 | bizjournals.com

Silicon Valley Technology News

See More Headlines

Receive BSTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioSpecifics Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2020
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:BSTC
CUSIP: 09093110
CIK: 875622
Web: www.biospecifics.com
Phone: 302-842-8450
Fax: N/A
Employees: 7
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $3.33
Trailing P/E Ratio: 37.51
Forward P/E Ratio: 61.91
P/E Growth: N/A
Net Income: $24.47 million
Net Margins: 47.43%
Pretax Margin: N/A
Return on Equity: 14.81%
Return on Assets: 14.46%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 66.24
Quick Ratio: 66.24

Sales & Book Value

Annual Sales: $38.19 million
Price / Sales: 17.03
Cash Flow: $3.38 per share
Price / Cash Flow: 26.18
Book Value: $18.42 per share
Price / Book: 4.81

Miscellaneous

Outstanding Shares: 7,345,000
Free Float: N/A
Market Cap: $650.25 million
Optionable: Not Optionable
Beta: 0.24

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Ronald Law J.D. (Age 67)
Ph.D., Sr. VP of Bus. Devel.
Comp: $487.38k
Mr. Joseph Truitt (Age 55)
CEO & Director
Mr. Patrick C. Hutchison (Age 61)
Chief Financial Officer
Mr. Alex Monteith
Sr. VP & Chief Bus. Officer
Carl A. Valenstein
Corp. Sec.

Key Competitors

View All Competitors

BSTC Stock Analysis - Frequently Asked Questions

How were BioSpecifics Technologies' earnings last quarter?: BioSpecifics Technologies Corp. (NASDAQ:BSTC) announced its quarterly earnings data on Saturday, November, 14th. The biopharmaceutical company reported $0.89 EPS for the quarter, topping analysts' consensus estimates of $0.19 by $0.70. The biopharmaceutical company had revenue of $11.26 million for the quarter, compared to analyst estimates of $5.46 million. BioSpecifics Technologies had a net margin of 47.43% and a trailing twelve-month return on equity of 14.81%.
What other stocks do shareholders of BioSpecifics Technologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioSpecifics Technologies investors own include AbbVie (ABBV), NVIDIA (NVDA), Pfizer (PFE), Biogen (BIIB), Johnson & Johnson (JNJ), Horizon Therapeutics Public (HZNP), Inovio Pharmaceuticals (INO), Intel (INTC), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

This page (NASDAQ:BSTC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BioSpecifics Technologies (BSTC) Stock Price, News & Analysis

About BioSpecifics Technologies Stock (NASDAQ:BSTC)

BSTC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

BSTC Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info